A phase II trial of murine monoclonal antibody 17-1A and interferon-γ : clinical and immunological data

• Published in: Cancer Immunology Immunotherapy 1990-05, Vol.32 (3), p.185-190
• Main Authors: SALEH, M. N, LOBUGLIO, A. .F, WHEELER, R. H, ROGERS, K. J, HAYNES, A, LEE, J. Y, KHAZAELI, M. B
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - blood; Adenocarcinoma - drug therapy; Adenocarcinoma - immunology; Adenocarcinoma - secondary; Animals; Antibodies, Monoclonal - therapeutic use; Antibody Formation - immunology; Antineoplastic agents; Biological and medical sciences; Colonic Neoplasms - blood; Colonic Neoplasms - drug therapy; Colonic Neoplasms - immunology; Colonic Neoplasms - secondary; Drug Evaluation; Humans; Immunotherapy; Interferon-gamma - therapeutic use; Interferon-gamma - toxicity; Leukocyte Count - drug effects; Medical sciences; Mice; Original; Pharmacology. Drug treatments; Recombinant Proteins
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/BF01771455

A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon gamma (0.1 mg/m2, days 1-15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.